First Derivation Of Human Embryonic Stem Cells Reported In Science

November 06, 1998

Geron Holds Worldwide License to a Breakthrough Discovery with Promise for Treating Degenerative Diseases

MENLO PARK, CA -- November 5, 1998 -- Human embryonic stem cells (hES cells) -- unique cells capable of forming all the different cell types and tissues in the body -- have been successfully derived and maintained in culture for the first time by scientists at the University of Wisconsin-Madison, according to an article to be published in the November 6 issue of the journal Science. The research was led by James A. Thomson, VMD, Ph.D., Developmental Biologist at UW-Madison, and was supported by and is licensed to Geron Corporation (NASDAQ:GERN).

"These cells are different from all other human stem cells isolated to date," said Dr. Thomson. "As the source of all cell types, they hold great promise for use in transplantation medicine, drug discovery and development, and the study of human developmental biology."

The Embryonic Stem Cell

Embryonic stem cells are derived from the inner cell mass of the blastocyst formed during early embryogenesis. Distinguished from all other stem cells, they are pluripotent, able to develop into virtually any and all cells and tissues in the body; and, consistent with their expression of telomerase, self-renewing, a potentially limitless source of cells.

"Geron is focused on developing products to treat age-related degenerative diseases. The availability of hES cells opens extraordinary opportunities for tissue transplantation, and for developing cell and gene therapy products with breakthrough medical potential," said Thomas Okarma, Ph.D., M.D., Geron's vice president of research and development. "Further, Gerons proprietary telomerase technology for prolonging the replicative lifespan of cells derived from hES cells positions the company to potentially supply the preferred cells for transplantation medicine."

Broad Potential for Medicine, Science and Drug Discovery

Human embryonic stem cells hold enormous promise for transplantation medicine because they can potentially produce unlimited quantities of any cell or tissue in the body. In addition, they may be genetically altered to improve therapeutic value, for instance, to prevent immune system rejection by transplant recipients. Examples of cells that Geron may develop for transplantation therapies include heart muscle cells for use in repairing the tissue damage inflicted by heart attacks, blood forming cells for use in bone marrow transplantation procedures for cancer patients, and nerve cells for use in treating patients with Parkinsons disease, stroke or Alzheimers disease.

Human embryonic stem cells also represent a new technology for pharmaceutical research and development. Geron plans to generate a variety of different cell types for use in drug screening and toxicology testing. In addition, hES cells can potentially be engineered to create in vivo models of human disease for drug development as a superior alternative to current mouse models. For example, brain neurons derived from hES cells might be engineered to develop the characteristics of Alzheimers disease and used to discover effective drug treatments.

Human embryonic stem cells should also further our understanding of embryonic development with potential applications toward the treatment of infertility and premature pregnancy loss, and the diagnosis and prevention of birth defects.

Finally, hES cells open the door to a new field of research -- the genomics of human developmental biology. Until now, early genetic events in human embryology have been largely inaccessible to direct observation. Research with hES cells may lead to the discovery of novel genes that fundamentally control tissue differentiation. These gene products could result in the development of therapeutic drugs and proteins with potential applications in wound healing, stroke, heart attack and spinal cord injury.

Collaborations with ES Cell Leaders

To accomplish its hES cell program objectives, Geron has established collaborations with renowned researchers in the field. The company funds research by and holds worldwide licensing agreements with John D. Gearhart, M.D., Ph.D., professor of gynecology and obstetrics at Johns Hopkins University School of Medicine, and Roger A. Pedersen, Ph.D., professor at the University of California, San Francisco.

Next steps in Geron's hES cell program include the development and optimization of enabling technologies. These include techniques for the production and scale up of hES cells; the identification of cell differentiation factors; techniques for genetically engineering hES cells, and the development of models to test proposed transplant products.

"As we pursue these next steps, Geron recognizes that research in this field should be conducted according to appropriate guidelines," said Ronald W. Eastman, Gerons president and CEO. "This discovery holds great promise for the treatment of a variety of human diseases and conditions. In concert with our Ethics Advisory Board and the Institutional Review Boards of our collaborators, Geron is committed to realizing the vast potential of this technology in a responsible manner."

Geron Corporation is a biopharmaceutical company focusing on discovering and developing therapeutic and diagnostic products based upon the company's understanding of human embryonic stem cells, and of telomeres and telomerase in cells -- fundamental biological platforms underlying cancer and other age-related degenerative diseases.

The company desires to take advantage of the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Specifically, the company wishes to alert readers that the matters discussed in this press release constitute forward-looking statements that are subject to certain risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect the company's results are included in the company's quarterly report on Form 10-Q for the quarter ended June 30, 1998.

Background Information:

Note to Editors: To receive a copy of this paper, contact Sciences News and Information office at (202) 326-6440. Further information on this announcement and Geron Corporation can be obtained at

Geron Corporation

Related Stem Cells Articles from Brightsurf:

SUTD researchers create heart cells from stem cells using 3D printing
SUTD researchers 3D printed a micro-scaled physical device to demonstrate a new level of control in the directed differentiation of stem cells, enhancing the production of cardiomyocytes.

More selective elimination of leukemia stem cells and blood stem cells
Hematopoietic stem cells from a healthy donor can help patients suffering from acute leukemia.

Computer simulations visualize how DNA is recognized to convert cells into stem cells
Researchers of the Hubrecht Institute (KNAW - The Netherlands) and the Max Planck Institute in Münster (Germany) have revealed how an essential protein helps to activate genomic DNA during the conversion of regular adult human cells into stem cells.

First events in stem cells becoming specialized cells needed for organ development
Cell biologists at the University of Toronto shed light on the very first step stem cells go through to turn into the specialized cells that make up organs.

Surprising research result: All immature cells can develop into stem cells
New sensational study conducted at the University of Copenhagen disproves traditional knowledge of stem cell development.

The development of brain stem cells into new nerve cells and why this can lead to cancer
Stem cells are true Jacks-of-all-trades of our bodies, as they can turn into the many different cell types of all organs.

Healthy blood stem cells have as many DNA mutations as leukemic cells
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ.

New method grows brain cells from stem cells quickly and efficiently
Researchers at Lund University in Sweden have developed a faster method to generate functional brain cells, called astrocytes, from embryonic stem cells.

NUS researchers confine mature cells to turn them into stem cells
Recent research led by Professor G.V. Shivashankar of the Mechanobiology Institute at the National University of Singapore and the FIRC Institute of Molecular Oncology in Italy, has revealed that mature cells can be reprogrammed into re-deployable stem cells without direct genetic modification -- by confining them to a defined geometric space for an extended period of time.

Researchers develop a new method for turning skin cells into pluripotent stem cells
Researchers at the University of Helsinki, Finland, and Karolinska Institutet, Sweden, have for the first time succeeded in converting human skin cells into pluripotent stem cells by activating the cell's own genes.

Read More: Stem Cells News and Stem Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to